# Bioequivalence Study of Esomeprazole From Stomopral 40 mg Capsules Contain Enteric Coated Pellets (Future Pharmaceuticals Industries, Egypt) and Nexium 40 mg Delayed Release Capsules (AstraZeneca Sweden, Product of France)

> **NCT05038969** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Stomopral
- **DRUG:** Nexium

## Key facts

- **NCT ID:** NCT05038969
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-18
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-05-28
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05038969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05038969, "Bioequivalence Study of Esomeprazole From Stomopral 40 mg Capsules Contain Enteric Coated Pellets (Future Pharmaceuticals Industries, Egypt) and Nexium 40 mg Delayed Release Capsules (AstraZeneca Sweden, Product of France)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05038969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*